ADVANCED THERAPIES XCHANGE
EAST COAST
Boston
April 3, 2023

Welcome to hubXchange’s Advanced Therapies Xchange 2023, East Coast, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in cell and gene therapeutics.

Discussion topics will cover Cell Tx Development, Gene Tx Development, C&G Tx Bioprocessing and C&G Tx Manufacturing.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Venue Details: Hilton Boston Woburn Hotel, 2 Forbes Road, Woburn MA 01801

Cell Tx Development

Time
Titles and Bullets
Facilitator
8:00 – 8:30am
Registration 
8:30 – 9:00am

Opening Address & Keynote Presentation

9:05 – 10:05am

Enhancing CAR-T cell efficacy

Director,Gene Therapy CMC
Development, PTC Therapeutics

10:10 – 10:40am
1-2-1 Meetings/Networking Break
10:40 – 11:10am
1-2-1 Meetings / Networking Break
11:10 – 11:20am
Morning Refreshments
11:20am – 12:20pm

Sponsored Roundtable

12:20 – 1:20pm

Networking Lunch

1:25 – 2:25pm

Alternatives to autologous- allogenic and in vivo cell therapies

CEO, Biocytogen Boston

2:30 – 3:00pm
1-2-1 Meetings / Networking Break
3:00 – 3:30pm
1-2-1 Meetings / Networking Break
3:30 – 3:45pm
Afternoon Refreshments

4:20 – 5:20pm

The Promise and Challenges of PSC-CAR-NK Cell Therapy

  • Promise: CAR-NK cells from pluripotent stem cells (PSC) will potentially provide an inexhaustible cell source of allogenic/off-the-shelf therapeutics for all patients worldwide.
  • Challenges: Tumorigenic potential from undifferentiated PSCs, CMC and manufacture; and limited sustainability in vivo.
  • Discussion points: Differentiation process and QA/QC; scalable manufacture; and gene editing strategy

President and CEO, HebeCell

John Lu, PhD, MPH, is the President and CEO of HebeCell Corporation, focusing on the development and pluripotent stem cell (PSC)-CAR-NK cells for the treatment of human diseases. Before establishing HebeCell, he was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics for 11 years. John has more than 20 years of experience in stem cell biology and regenerative medicine as well as >10 year experiences in cancer research. John is the inventor of more than 20 patents in stem cell field: in an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, John’s patent application and citation ranked No. 7 and No. 5, respectively.

John Lu
5:20 – 6:20pm
Drinks/Canape Reception

Partners

Advanced Therapies Xchange | East Coast 2023
Register